About Us

Any time someone is diagnosed with cancer, many decisions have to be made regarding development of an optimal personalized treatment plan. Development of an optimal treatment plan requires accurate information regarding the diagnosis, prognosis and predicted responsiveness of a specific tumor – in other words accurate staging of the tumor. This information comes from several sources such as a physician's judgment based upon the physical signs and symptoms of a patient, traditional laboratory testing, and newer molecular testing.

Accurate information is required because all treatment plans (such as surgery, radiation, drug-therapy, surveillance, and even watching and waiting) have benefits and risks that the physician and patient need to weigh. These considerations help to determine an optimal treatment plan for that patient with that tumor at that time. Some cancers exhibit very little variation from patient to patient in terms of prognosis and predictive responsiveness. This means that the diagnosis, prognosis and predictive responsiveness achieved by traditional laboratory tests may be entirely appropriate to design an optimal treatment plan for a specific patient. Many cancers, however, exhibit a large variation in prognosis and predictive responsiveness from patient to patient. Often accurate information cannot be obtained through traditional laboratory testing alone – these cancers require the use of newer molecular tests to enable development of an optimal personalized treatment plan. Many common cancers have such molecular testing options available.

Unfortunately, development of molecular testing for rare cancers lags behind the advances made in common cancers. Sometimes testing has been developed in a given cancer institution and may be available only to patients treated at that institution.

At Castle Biosciences, we focus on addressing this gap. We work with leading cancer institutions to in-license proprietary technologies and complete development and validation. The ultimate goal is to make these proven tests available to all individuals afflicted with a rare cancer.

Licensing Opportunities

We are constantly responding to inquiries from leading cancer institutions regarding their technologies that may be appropriate for the patient afflicted with a rare cancer.

We use the following template when evaluating license opportunities:

Tests in development focus on cutaneous melanoma, esophageal cancer, and BAP1 testing.

In Development

Development efforts for: DecisionDx-EC

The DecisionDx-EC test, discovered at The University of Texas MD Anderson Cancer Center, has completed three independent clinical validation studies for predicting extreme resistance to pre-operative chemoradiation therapy with very high accuracy in patients with esophageal cancer (Ajani, 2011; Lassen, 2013; Shan, 2014; Shan, 2014; Badve, 2014). Castle Biosciences is continuing development work with DecisionDx-EC to potentially expand the utility of this test to include predicting which patients may have a complete pathologic response to pre-operative chemoradiation therapy.

Preliminary data suggests that this assay may also have application in rectal adenocarcinoma cancers (Badve, 2014).

The DecisionDx-EC test is not currently available for clinical use while we are moving our facilities. We expect to have the move completed to be able to offer this laboratory developed test in the near future.

For inquiries, please contact us at 866-788-9007.

Development efforts for BAP1

The role of BAP1 in metastasis in uveal melanoma was recently discovered by Drs. Harbour and Bowcock at Washington University (link). Castle Biosciences exclusively licensed the use of BAP1 in uveal melanoma and cutaneous melanoma from Washington University and is completing development of the technology as a tool for identifying patients who may be responsive to certain treatments as well as inherited risk for risk of uveal melanoma, cutaneous melanoma, mesothelioma and other cancers (so called germ line testing). Castle compared BAP1 testing as a predictor of metastasis in uveal melanoma to their DecisionDx-UM test. The analysis confirmed that the DecisionDx-UM test is superior to BAP1 testing for predicting the risk of metastasis in uveal melanoma. The company also plans to investigate the role of BAP1 in metastasis of other cancers.

Development efforts for: DecisionDx-Mesothelioma

Mesothelioma is a rare cancer that creates diagnostic and prognostic challenges. Standard of care includes surgical resection which is a complex procedure involving significant recovery time, with or without adjuvant therapy. Unfortunately, only some patients experience significant benefit from these standard of care interventions.

The new DecisionDx-Mesothelioma molecular test combines clinical characteristics with gene expression profiling to provide the most accurate survival prediction for patients diagnosed with malignant pleural mesothelioma. Building on initial discovery and validation work performed at Brigham & Women’s Hospital, Castle Biosciences licensed the test and recently completed clinical validation. The DecisionDx-Mesothelioma test was found to be an objective, independent predictor of risk associated with mesothelioma compared to clinical and histologic factors. When used alone, or in conjunction with other clinical parameters, the DecisionDx-Mesothelioma test can help discern prognosis and thus assist with treatment planning.

The DecisionDx-Mesothelioma molecular test is only available through Castle Bioscineces. The test is currently available to physicians and their patients as a CLIA-approved test.

Castle Biosciences believes that use of its tests should be based on the need for prognostic information rather than on a patient's ability to pay. Because of this, the Company has an access program that supports this philosophy. Please call 866-788-9007 to learn more.

Our Team

Derek Maetzold, President and CEO

Derek is founder, President, CEO, and Board member of Castle Biosciences, Inc. He has been a leader in biopharmaceuticals for over 25 years, working in increasing leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals and Sandoz (now Novartis). Derek started in field sales, completed assignments in marketing, new product development, business development, commercialization strategy and completed his tenure prior to Castle Biosciences at Encysive as Officer and Vice President, Marketing and Sales. Derek attended George Mason University, where he received a BS in Biology before completing additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside.

James L. Dunn, Jr, CPA, Chief Financial Officer

Jim is Chief Financial Officer of Castle Biosciences. He has over 20 years of combined accounting and legal experience as a public company executive. Jim has held positions as CFO and General Counsel in a variety of industries including healthcare, technology and manufacturing, with responsibilities including SEC reporting, investor relations and compliance. Most recently as CFO of Applied Optoelectronics he successfully managed the company’s IPO and follow-on offering. He began his public company tenure as a co-founder and CFO of Pentegra Dental Group (now iLinc) from its IPO in 1998 until iLinc was successfully sold ten years later. Jim is a certified public accountant and attorney. He holds a Bachelor of Business Administration – Accounting from Texas A&M University, and received his JD degree from Southern Methodist University.

Toby Juvenal, Vice President, US Sales and Marketing

Toby is the Vice President, US Sales and Marketing at Castle Biosciences, Inc. He has over 20 years of sales, sales management, and managed care experience in the pharmaceutical, biotechnology and diagnostics industries. He has held multiple management positions at decode Genetics, Encysive Pharmaceuticals and Genzyme Pharmaceuticals after beginning his pharmaceutical career at Stuart (now AstraZeneca). Toby attended the University of Florida where he received a BS in Marketing.

Kristen Oelschlager, RN, Vice President, Operations

Kristen is the Vice President of Operations at Castle Biosciences. Kristen brings over 15 years' experience in the field of nursing, clinical services, management and leadership including the start-up and growth management of a multi-location hospital and outpatient based clinical research department. Kristen joins Castle with a strong history of process management under strict QA/QC/SOP. Kristen attended Purdue University, where she completed her core nursing requirements, prior to receiving her Associate of Science, Nursing from the Indiana Vocational Technical College. She recently completed a program as a Legal Nurse Consultant and has held certification as a Clinical Research Coordinator. Kristen has been a speaker for Actelion Pharmaceuticals, Eli Lilly, and Encysive Pharmaceuticals and is a published author.

Robert W. Cook, PhD, Manager, Scientific Relations

Bob joined Castle as Manager of Scientific Relations. Bob brings over fifteen years of experience and training in academic and industrial science. Bob has an extensive background in molecular biology and genetics. He received his B.S. Degree in Biology from Temple University in Philadelphia, and his Ph.D. degree from Northwestern University for his studies of the structural characteristics of protein hormones important for regulating the reproductive system. Bob comes to Castle following a postdoctoral fellowship at Baylor College of Medicine that was focused on the genetic regulation of rare ovarian granulosa cell tumors. Prior to pursuing his doctoral degree, Bob spent five years (1995-2000) at Gen-Probe, Incorporated as a member of their Product Transfer Department and in the Research and Development Department, designing diagnostic assays using Gen-Probe's patented nucleic acid amplification technology.

Board of Directors

Dan Bradbury, Board Chair

Mr. Bradbury is a Life Sciences Executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a Life Sciences Consulting and Investment Firm.

Mr. Bradbury is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He also serves on the board of directors of Corcept Therapeutics (CORT), Geron Corporation (GERN), Illumina, Inc. (ILMN) and Castle Biosciences, Inc., the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee.

Mr. Bradbury currently serves on the University of California San Diego’s Rady School of Management's Advisory Council, the RAND Health Board of Advisors and the University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

Joe C. Cook, Jr, Board Member

Mr. Cook is a principal and co-founder of Mountain Group Capital. Mr. Cook is a founder and Past-Chairman of the Board of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) a biotechnology company in Cambridge, MA where he continues to serve as a director. Also, Mr. Cook serves as a director of Corcept Therapeutics, Inc. (NASDAQ: CORT) a biopharmaceutical company in Palo Alto, CA. Mr. Cook served as Chairman of Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) from 1998 to 2009 and was Chief Executive Officer from 1998 to 2003. In 2009, Mr. Cook received the Pinnacle Award for Life Science Leadership from the Rady School of Management at the University of California at San Diego.

Mr. Cook retired as a Group Vice-President, Global Operations, of Eli Lilly and Company in 1993 after more than 28 years of service. During his career at Lilly he served in various senior executive positions including: manufacturing, engineering, finance, sales and marketing and general management. Mr. Cook took a leave of absence from Eli Lilly and Co. in 1976 and was employed by the US International Trade Commission in Washington, DC as a part of the President’s Executive Exchange Program.

Mr. Cook serves as Chairman of the Board of Mercy Ministries International, Inc. with headquarters in Nashville, TN. He is also a past Chair and current member of the University of Tennessee College of Engineering Advisory Board. In 1999, Mr. Cook received the Nathan W. Dougherty Award from the University of Tennessee for distinguished service in the engineering profession. Mr. Cook also serves on the national board of the American Diabetes Association and is Chairman of the board of Life Science Tennessee. Mr. Cook also serves as Chairman of Diabetes Care Group and on the boards of Castle Biosciences and Clinical Products. He was a co-founder and serves on the boards of Device Innovation Group and Diagnovus.

Mr. Cook graduated from the University of Tennessee in 1965 where he received a BS in Engineering with High Honors and was a UT Torchbearer.

Garheng Kong, MD, PhD, Board Member

Dr. Kong is the Founder and Managing Partner of HealthQuest Capital, a healthcare focused investment firm, and has been a healthcare investor since 2000. He was a General Partner at Sofinnova Ventures and Intersouth Partners. Dr. Kong has served as chairman and director on the boards of numerous companies, and operated as interim CEO for two venture-backed companies. Specifically, he served as the founding investor and Chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline), Chairman of Cempra Pharmaceuticals (Nasdaq: CEMP), and lead investor of the first financing for Alimera Sciences (Nasdaq: ALIM). Dr. Kong has also led investments in Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation (Nasdaq: AGTC), TransEnterix (NYSE: TRXC), Calibra Medical (acquired by J&J), Athenix (acquired by Bayer, board observer), Aldagen (acquired by Cytomedix), Histogenics (Chairman), Salveo Specialty Pharmacy, SARcode Bioscience Inc. (acquired by Shire) and First Aid Beverages, Inc. Additionally he sits on the board of Laboratory Corporation of America (NYSE: LH) and the Duke University Medical Center Board of Visitors.

Dr. Kong serves or has served on the boards of directors of the SEBIO organization, the North Carolina Biotechnology Center, the Council for Entrepreneurial Development (CED), the Hamner Institutes for Life Sciences, the North Carolina Medical Device Organization, the University of Florida Biotechnology Council, the University of Virginia Ivy Foundation, the Pennsylvania Life Sciences Greenhouse, the Southeast Universities Research Association, the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, Corporate Chaplains of America and the Duke Medical Center Institutional Review Board (IRB).

Prior to his investing career, Dr. Kong spent time at GlaxoSmithKline, McKinsey & Company, and TherOx. He received his M.D. (Medical Scientist Training Program), Ph.D. in Biomedical Engineering, and M.B.A. from Duke University, where he also served on the faculty. He also holds B.S. degrees in Chemical Engineering and Biological Sciences from Stanford University.

Derek Maetzold, President, CEO, and Board Member

Mr. Maetzold is the founder, President, CEO, and Board member of Castle Biosciences, Inc.

He has been a leader in biopharmaceuticals for over 25 years, working in leadership roles in both biotechnology and traditional pharmaceutical companies. Prior to founding Castle Biosciences, Mr. Maetzold was an Officer and Vice President, Marketing and Sales at Encysive Pharmaceuticals, a publicly traded company that was acquired by Pfizer. Prior to Encysive, Mr. Maetzold worked in business development and new product development at Schering Corporation (now Merck). Previous experience included positions at Integrated Communications, Amylin Pharmaceuticals (now BMS) and Sandoz (now Novartis). Derek started in field sales at Sandoz, eventually working into leadership positions in both U.S. and international marketing.

Mr. Maetzold attended George Mason University, where he received a BS in Biology before completing additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside.

Institutional Investors:

Mountain Group Capital and Affiliates

HealthQuest Capital

Longfellow Venture Partners I

State of Texas Emerging Technology Fund

Scientific Advisory Board

We are completing development of several new technologies. We will be structuring our Scientific Advisory Board to meet the needs of these new technologies and making announcements shortly.

Home Company Tests Resources Contact Physician Login